The International Myeloma Foundation (IMF) will host the 9th Annual International Myeloma Working Group (IMWG) Summit from June 11–13 in Stockholm, Sweden. More than 100 of the world’s top myeloma experts will attend the 2018 Summit, which convenes on the eve of the 23rd Annual Congress of the European Hematology Association (EHA), also in Stockholm. Throughout the IMWG Summit, myeloma experts will debate how best to treat patients in 2018 and beyond.
At the Summit, working groups will tackle significant questions surrounding multiple myeloma, an approach that regularly results in the publication of well-respected IMWG treatment guidelines used by physicians and cited by researchers hundreds of times annually.
The Summit provides the opportunity for us to evaluate the latest developments in myeloma research and treatment, and come to a consensus on how best to incorporate these advances into recommendations for improving treatment for myeloma patients globally.
From CAR T-cell therapy to testing technologies
Topics we will address in Sweden include CAR T-cell therapy and other immune therapy approaches; the best treatment for early relapse; the role of transplant; and innovative new myeloma testing technologies. In addition, investigators from the IMF’s Black Swan Research Initiative® (BSRI) team will meet to determine the next steps in the IMF’s effort to find the pathway to cure myeloma.
Patients, caregivers, and doctors around the world can watch a live-stream broadcast from the Summit on Wednesday, June 13. During the IMF’s popular IMWG Conference Series, "Making Sense of Treatment," Dr. María-Victoria Mateos, IMF Chief Medical Officer Dr. Joseph Mikhael, and myself will distill, debate, and discuss up-to-the minute myeloma news from the Summit, from the European Hematological Association (EHA) meeting, and from the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). This 60-minute live webcast will start at 6 a.m. EST. An archived version will also be available.
Additional highlights from Stockholm include:
- Presentation of the IMF’s Annual IMWG Awards. Prof. Philippe Moreau, MD, will receive the 16th Annual Robert A. Kyle Lifetime Achievement Award. The award honors an individual whose body of work has made significant contributions to myeloma research and patient care. Dr. Sigurdur Y. Kristinsson will receive the inaugural Brian G.M. Durie Outstanding Achievement Award, which recognizes excellence in myeloma research.
- The IMF Global Myeloma Action Network (GMAN) Summit. More than 30 myeloma patient groups from around the world will gather to raise global awareness of myeloma, improve patient outcomes, and ensure access to life-saving treatments.
As the IMF President Susie Novis Durie says, “The IMF is proud to lead this unprecedented collaborative event that brings together the world’s experts in myeloma to advance treatment and research that will lead to a cure.”
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.